FLT3 and acute myeloid leukemia: Even the FLT3 pathway, representing currently a target for patients with AML and advanced systemic mastocytosis,97 has been associated with the expansion and function of MDSCs98; therefore the potential alterations of MDSCs in patients treated with the FLT3 inhibitor midostaurin remain to be investigated.